Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|April 28, 2014
Rebiopsying for Prostate Cancer
Author(s)E. David Crawford, MD
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.
Advertisement
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.
Clinical Pearls:
- Each year in the U.S., 1.3-1.4 million biopsies are performed for prostate cancer, with only 240,000 leading to diagnoses
- The need for a test to determine which men should be rebiopsied may have been answered by the ConfirmMDx test
- Methylation tests look for DNA changes in normal tissue on a biopsy that potentially was around the cancer
- If the test is negative and no genes are methylated, the physician is presented with a 90%-plus positive predictive value that the man does not have cancer. If the test is negative and the man does have cancer, it is typically low-grade and would not be treated anyway.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5